HBM Healthcare Investments Invests USD 4.5 Million in Lycia Therapeutics IPO

• HBM Healthcare Investments invested USD 4.5 million in Lycia Therapeutics' IPO, bringing its total investment to USD 13.5 million.
• Its initial USD 9 million investment came in June 2026 through Series D financing; its post-IPO stake is approximately 2.2%.
• The stake was valued at USD 36.8 million at the first-day closing price of USD 30, up 66.7% from the IPO price.
• Lycia raised gross proceeds of USD 317.5 million by issuing 17,640,000 new shares at USD 18 each.
• Shares began trading on the Nasdaq Global Select Market on October 23, 2026, under the ticker LYCA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2421760_en) on October 26, 2026, and is solely responsible for the information contained therein.